Diversify Advisory Providers LLC minimize its place in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.1% in the course of the third quarter, in line with the corporate in its most up-to-date submitting with the SEC. The agency owned 57,735 shares of the corporate’s inventory after promoting 1,824 shares in the course of the quarter. Diversify Advisory Providers LLC’s holdings in Johnson & Johnson have been price $9,437,000 as of its most up-to-date submitting with the SEC.
Different hedge funds additionally not too long ago modified their holdings of the corporate. Innealta Capital LLC acquired a brand new place in shares of Johnson & Johnson in the course of the 2nd quarter valued at $27,000. Mowery & Schoenfeld Wealth Administration LLC elevated its place in shares of Johnson & Johnson by 58.7% in the course of the third quarter. Mowery & Schoenfeld Wealth Administration LLC now owns 246 shares of the corporate’s inventory valued at $40,000 after buying a further 91 shares in the course of the interval. Morton Brown Household Wealth LLC elevated its place in shares of Johnson & Johnson by 400.0% in the course of the third quarter. Morton Brown Household Wealth LLC now owns 250 shares of the corporate’s inventory valued at $41,000 after buying a further 200 shares in the course of the interval. MFA Wealth Advisors LLC purchased a brand new stake in shares of Johnson & Johnson in the course of the 2nd quarter price $43,000. Lastly, Fairfield Monetary Advisors LTD purchased a brand new stake in shares of Johnson & Johnson in the course of the 2nd quarter price $46,000. 69.55% of the inventory is at the moment owned by institutional traders and hedge funds.
Johnson & Johnson Value Efficiency
Shares of NYSE:JNJ opened at $160.62 on Thursday. The corporate has a present ratio of 1.07, a fast ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1 yr low of $143.13 and a 1 yr excessive of $168.85. The enterprise has a fifty day easy shifting common of $163.44 and a 200 day easy shifting common of $155.32. The agency has a market cap of $386.56 billion, a price-to-earnings ratio of 10.01, a P/E/G ratio of two.90 and a beta of 0.52.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final posted its earnings outcomes on Tuesday, October fifteenth. The corporate reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on fairness of 35.46% and a web margin of 19.14%. The corporate had income of $22.47 billion for the quarter, in comparison with analyst estimates of $22.17 billion. Throughout the identical interval final yr, the corporate earned $2.66 earnings per share. The enterprise’s income was up 5.2% in comparison with the identical quarter final yr. As a bunch, sell-side analysts predict that Johnson & Johnson will put up 9.94 earnings per share for the present fiscal yr.
Johnson & Johnson Pronounces Dividend
The enterprise additionally not too long ago introduced a quarterly dividend, which will likely be paid on Tuesday, December tenth. Shareholders of document on Tuesday, November twenty sixth will likely be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November twenty sixth. This represents a $4.96 annualized dividend and a yield of three.09%. Johnson & Johnson’s dividend payout ratio (DPR) is at the moment 30.92%.
Analyst Scores Modifications
JNJ has been the topic of a number of analysis experiences. TD Securities lowered their worth goal on Johnson & Johnson from $195.00 to $185.00 in a analysis be aware on Thursday, July 18th. Cantor Fitzgerald reissued an “obese” ranking and set a $215.00 worth goal on shares of Johnson & Johnson in a analysis be aware on Wednesday, October sixteenth. Citigroup raised their worth goal on Johnson & Johnson from $180.00 to $185.00 and gave the inventory a “purchase” ranking in a analysis be aware on Wednesday, October sixteenth. Sanford C. Bernstein raised their worth goal on Johnson & Johnson from $161.00 to $171.00 in a analysis be aware on Thursday, July 18th. Lastly, Daiwa Capital Markets minimize Johnson & Johnson from an “outperform” ranking to a “impartial” ranking and decreased their goal worth for the inventory from $160.00 to $150.00 in a analysis report on Tuesday, July twenty third. Six equities analysis analysts have rated the inventory with a maintain ranking, seven have issued a purchase ranking and one has issued a robust purchase ranking to the corporate’s inventory. Based on MarketBeat, Johnson & Johnson has a consensus ranking of “Reasonable Purchase” and a mean goal worth of $175.93.
Learn Our Newest Analysis Report on JNJ
Insider Shopping for and Promoting at Johnson & Johnson
In different Johnson & Johnson information, VP Robert J. Decker offered 5,635 shares of the agency’s inventory in a transaction dated Friday, August thirtieth. The inventory was offered at a mean worth of $165.06, for a complete transaction of $930,113.10. Following the transaction, the vice chairman now instantly owns 18,973 shares within the firm, valued at $3,131,683.38. This commerce represents a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a submitting with the Securities & Change Fee, which is offered at the SEC web site. Company insiders personal 0.16% of the corporate’s inventory.
Johnson & Johnson Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells varied merchandise within the healthcare subject worldwide. The corporate’s Progressive Drugs section affords merchandise for varied therapeutic areas, akin to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, akin to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension via retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Tales
Wish to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Each day – Enter your e mail tackle under to obtain a concise every day abstract of the newest information and analysts’ scores for Johnson & Johnson and associated firms with MarketBeat.com’s FREE every day e mail publication.
